Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Income from Continuing Operations
Sonoma Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Income from Continuing Operations
-$5.1m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
2%
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$18.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
$8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
$2.2B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-15%
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$377m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-22%
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$5.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
See Also
What is Sonoma Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-5.1m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Income from Continuing Operations amounts to -5.1m USD.
What is Sonoma Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
2%
Over the last year, the Income from Continuing Operations growth was 25%. The average annual Income from Continuing Operations growth rates for Sonoma Pharmaceuticals Inc have been -20% over the past three years , 18% over the past five years , and 2% over the past ten years .